Pharmaceuticals company Laurus Labs announced H1FY25 results H1 Revenues Rs 2,419 crore and 1% revenue growth, performance on track to deliver Full Year growth outlook driven by scheduled project deliveries in CDMO. Rs 353 crore EBITDA resulted in a margin of 14.6%, impacted by lower asset utilization and upfront cost absorption in growth projects. Gross margins maintained at healthy levels of 55.1%, improving 3.5% pts over last year. Q2 Revenues Rs 1,224 crore and flattish revenue growth, Rs 182 crore EBITDA resulted in a margin of 14.9%, Gross margins at healthy levels of 55.2%. Encouraging demand for CMO/CDMO integrated service offering and complex APIs; pipeline momentum healthy. CAPEX investments across key growth projects progressing as planned, to support long term growth. FY25 outlook maintained; We expect better H2 reflecting facility ramp up, delivery of late-phase NCE projects and EBITDA margins improvement. Satyanarayana Chava, Founder & Chief Executive Officer said: “We are pleased to see sustained demand in our CMO/CDMO services, supported by ongoing operational excellence and expanding platform capabilities. Opening of new R&D; center significantly advances our one-stop ‘D & M’ capability in meeting global partner diverse needs and growing early phase enquiries. Q2 results demonstrates continued resilience in financial health, led by strong growth in CDMO vertical offset by lower sales in ARV and Oncology API business. We remain committed to deliver on key NCE opportunities in H2, which is in line with our Full year growth outlook. Looking at industry fundamentals, we are well positioned to capture value by maintaining our focus on solving customer complex needs and deliver long-term stakeholder value” V V Ravi Kumar, Executive Director & Chief Financial Officer said: “During Q2, we delivered Rs 1,224 crore in revenues and Rs 182 crore EBITDA, resulting to 14.9% margin. Gross margins maintained healthy at 55.2% due to favorable CDMO mix and process optimization. Operating results affected from lower utilization of assets as we continue to prioritise resources towards delivering several complex projects at various clinical phases. Soft H1 performance, in line with expectations. We achieved Rs 2,419 crore in revenues, representing 1% revenues growth, and Rs 353 crore EBITDA, resulting in 14.6% margin. Gross margins improved by over 3.5% pts to 55.1% indicating robust business health. Overall, Net Debt has increased over last year due to continued CAPEX investments in expanding CMO capability. However, with a better H2 performance, supported by facility ramp up, and margin improvements, we expect reduction in Netdebt leverage by end of the year.” Result PDF